보건복지부 영문홈페이지

The 2024 KoNECT International Conference to Be Held

as a Hub for Global Clinical Trial Exchange

 

- Asia's largest international clinical trial conference to be held at Seoul Dragon City

from Tuesday, October 29, to Thursday, October 31 -

 

- Presenting efficient clinical trial cases and collaboration models for innovative drug development -

 

The Ministry of Health and Welfare (MOHW, Minister Cho KyooHong) and the Korea National Enterprise for Clinical Trials (KoNECT, President Park In-seok) announced that the 10th KoNECT International Conference (KIC) will take place from Tuesday, October 29, to Thursday, October 31, at Seoul Dragon City.

 

Celebrating its 10th anniversary, the KoNECT International Conference has grown into Asia's largest clinical trial conference, drawing approximately 1,300 experts in new drug development from around 350 Korean and international biotech firms, pharmaceutical companies, clinical researchers, regulatory agencies, and clinical research organizations (CROs).

 

The event will feature various programs under the theme "Integrating the Past, Present, and Future: Advancing Drug Development through Innovation," including an academic conference, a clinical trial policy forum, exhibitions and partnering sessions, a clinical trial job fair, and a seminar focused on clinical trials in Asia and the Middle East.

 

Notably, global pharmaceutical leaders Eisai and Eli Lilly will present innovative methodologies and strategies for new drug development, which is expected to greatly benefit Korean pharmaceutical companies. Conference programs will address the creation of a healthy clinical trial ecosystem, covering topics such as new trial technologies, pathways for global expansion, and strategies for new drug development.

 

In his opening remarks, 2nd Vice Minister of Health and Welfare Park Minsoo stated, “Global companies are showing great interest in Korea’s clinical trial capabilities and pharmaceutical and bio industries, so we expect the KoNECT International Conference to offer vital opportunities for our companies with next-generation innovative clinical technologies to expand globally.” He emphasized that “this conference will serve as a platform for open innovation, aimed at strengthening global capabilities in clinical trials and research collaboration.”

 

“The government will provide steadfast support for fostering an ecosystem for innovative drug development by training convergence talent in the pharmaceutical and bio sectors, offering institutional support for innovative drugs, investing strategically in R&D, promoting digital technology advancements such as AI and big data in drug development, and enhancing investment and export support for the pharmaceutical and bio industries,” he added.

 

Park In-seok, President of KoNECT, expressed in his opening remarks, “I hope this 2024 KoNECT International Conference will be a forum for Korean and international researchers, companies, and institutions in the biohealth industry to share the latest technologies and strategies in clinical trials and new drug development and to explore collaborative opportunities.”

 

He added, “I hope this conference will serve as an important platform for showcasing Korea’s outstanding clinical trial capabilities and innovative technologies on the global stage.” ///